Happy 100th episode subscribers! We bring you part 1 of a special double episode following our chat with Professor Kate Schroder, head of the Inflammasome Laboratory and Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland and Professor Ian Henderson, the Director of IMB. We explore the story behind the milestone research discovery that could lead to a treatment for conditions like Parkinson’s and Alzheimer’s disease, Motor Neurone Disease – even asthma. The innovation was developed out of the UQ, in partnership with Trinity College in Dublin. And the start-up company spawned by the research – Inflazome -- was recently acquired by Roche in a deal worth around $600 million, making it one of Australia’s largest ever biotech deals. We also explore the broader work of IMB and the international collaborative approach underpinning its research successes.